Bone loss after denosumab discontinuation is prevented by alendronate and zoledronic acid but not risedronate: a retrospective study

[1] Cummings SR(2009)Denosumab for prevention of fractures in postmenopausal women with osteoporosis N Engl J Med 361 756-765

[2] San Martin J(2017)10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension Lancet Diabetes Endocrinol 5 513-523

[3] McClung MR(2017)Observations following discontinuation of long-term denosumab therapy Osteoporos Int 28 1723-1732

[4] Bone HG(2018)Significant bone loss after stopping long-term denosumab treatment: a post FREEDOM study Osteoporos Int 29 41-47

[5] Wagman RB(2008)Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial Bone 43 222-229

[6] Brandi ML(2011)Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass J Clin Endocrinol Metab 96 972-980

[7] McClung MR(2016)Severe spontaneous vertebral fractures after denosumab discontinuation: three case reports Osteoporos Int 27 1923-1925

[8] Wagman RB(2017)Severe rebound-associated vertebral fractures after denosumab discontinuation: 9 clinical cases report J Clin Endocrinol Metab 102 354-358

[9] Miller PD(2017)Clinical features of 24 patients with rebound-associated vertebral fractures after denosumab discontinuation: systematic review and additional cases J Bone Miner Res 32 1291-1296

[10] Wang A(2018)Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM Trial and its extension J Bone Miner Res 33 190-198

[1] Cummings SR(2009)Denosumab for prevention of fractures in postmenopausal women with osteoporosis N Engl J Med 361 756-765

[2] San Martin J(2017)10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension Lancet Diabetes Endocrinol 5 513-523

[3] McClung MR(2017)Observations following discontinuation of long-term denosumab therapy Osteoporos Int 28 1723-1732

[4] Bone HG(2018)Significant bone loss after stopping long-term denosumab treatment: a post FREEDOM study Osteoporos Int 29 41-47

[5] Wagman RB(2008)Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial Bone 43 222-229

[6] Brandi ML(2011)Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass J Clin Endocrinol Metab 96 972-980

[7] McClung MR(2016)Severe spontaneous vertebral fractures after denosumab discontinuation: three case reports Osteoporos Int 27 1923-1925

[8] Wagman RB(2017)Severe rebound-associated vertebral fractures after denosumab discontinuation: 9 clinical cases report J Clin Endocrinol Metab 102 354-358

[9] Miller PD(2017)Clinical features of 24 patients with rebound-associated vertebral fractures after denosumab discontinuation: systematic review and additional cases J Bone Miner Res 32 1291-1296

[10] Wang A(2018)Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM Trial and its extension J Bone Miner Res 33 190-198